Related by context. All words. (Click for frequent words.) 77 Pharmacologic 69 Anti Tumor 69 Antiangiogenic 68 Antipsychotic 68 Cannabinoid 68 Neuroprotective 66 Antitumor 66 Immunomodulatory 66 Inhibitory 66 Cytotoxic 66 Antihypertensive 66 Androgen 66 Pharmacodynamics 66 Pharmacodynamic 66 Low Dose 66 Receptor Antagonists 66 Carbamazepine 65 Cyclooxygenase 2 65 Aurora Kinase 65 Prolongs Survival 65 antineoplastic 65 Valproic acid 65 Diabetic Nephropathy 65 Neuroprotection 65 Fondaparinux 65 Cytochrome P# 64 Factor Receptor 64 neuroleptic 64 Tyrosine Kinase Inhibitor 64 Anticancer 64 Mimetics 64 Bosutinib 64 Clinical Efficacy 64 Potent Inhibitor 64 antitumoral 64 Dendritic Cells 64 Epidermal Growth Factor Receptor 64 See CLINICAL PHARMACOLOGY 64 pharmacokinetic interactions 64 anticholinergic agents 64 selective inhibition 64 Benign Prostatic Hyperplasia 64 Aliskiren 64 Pharmacokinetics 64 Antiplatelet 64 extracellular dopamine 64 Anti VEGF 64 Glucocorticoids 64 Interferon Beta 63 pharmacological 63 Enzastaurin 63 Histone 63 Demonstrates Efficacy 63 Decitabine 63 Dehydrogenase 63 selective modulator 63 Homeostasis 63 somatostatin analogs 63 guanfacine extended release 63 5 HT6 receptor 63 Androgen Receptor 63 Recombinant Human 63 vasoactive 63 Tiotropium 63 Cardiotoxicity 63 Female Sexual Arousal 63 Phosphorylation 63 Skeletal Muscle 63 Corticosteroid 63 Thiazolidinediones 63 Fulvestrant 63 Orally Active 63 renoprotective 63 Cinacalcet 63 Treating Chronic 63 Adjunctive 63 Hematological 63 Anticancer Drug 63 TNFalpha 63 fosbretabulin 63 factor TNF 63 Anthracycline 63 Retinoic Acid 63 experimental allergic encephalomyelitis 63 Reductase 63 Proteasome 62 Clinical Outcome 62 Oral Formulation 62 Antisense 62 Anticoagulant 62 Transcriptional 62 Atomoxetine 62 Glucocorticoid 62 Liposomal 62 Modulates 62 Antifungal 62 Novel Oral 62 Novel Mechanism 62 Anti Angiogenic 62 Overactive Bladder 62 Non Steroidal Anti Inflammatory 62 Ranolazine 62 Relapsing Multiple Sclerosis 62 Bortezomib 62 NMDA antagonists 62 Estrogen Receptor 62 Pegylated 62 Superoxide 62 Anticholinergic 62 cis retinoic acid 62 Pulmonary Arterial Hypertension 62 Insulin Secretion 62 Antidiabetic 62 selective antagonist 62 Trandolapril 62 Immunotherapeutic 62 Attenuates 62 prostanoid 62 Receptor Antagonist 62 Antitumor Activity 62 Generalized Anxiety Disorder 62 Intracellular 62 Allergic Rhinitis 62 Transcription Factor 62 PKC# 62 Valsartan 62 flavopiridol 62 Clinical Trial Results 62 receptor antagonists 62 Lacosamide 62 plasma pharmacokinetics 62 Small Molecule 62 Therapeutic Potential 62 antidepressive 62 phosphodiesterase inhibitors 62 tricyclic 62 antidiabetic 62 Adenosine 62 erythropoietic 62 cyclooxygenase 2 62 JAK Inhibitor 62 Oligonucleotides 62 Controlled Trial 62 Anticonvulsant 62 Aripiprazole 62 Nilotinib 62 calcitonin gene related 62 LPS induced 62 Akathisia 62 antiinflammatory 61 pharmacodynamic parameters 61 vWF 61 Dalbavancin 61 Kinase Inhibitors 61 Kinase Inhibitor 61 Hepatic 61 acadesine 61 effector function 61 immunomodulatory agents 61 Natalizumab 61 antiangiogenic 61 Endothelial 61 Enzyme Replacement Therapy 61 Nebulized 61 Neuropsychological 61 Motility 61 Hippocampal 61 microtubule targeting 61 Cytotoxicity 61 Analgesic 61 Aldosterone 61 Double Blind Randomized 61 Muscarinic 61 Oxidative 61 beta adrenergic 61 serotonergic 61 Denufosol 61 Malignant Glioma 61 Bioavailability 61 Intervention Effectiveness 61 BAL# [002] 61 Plaque Psoriasis 61 muscarinic 61 Pharmacotherapy 61 Hepatotoxicity 61 Oncogenic 61 Phase IIA 61 Uric Acid 61 Thyroid Hormone 61 antiapoptotic 61 Sugammadex 61 Transdermal Delivery 61 clomipramine 61 anxiolytic 61 Preclinical Data 61 mTOR mammalian target 61 Thrombotic 61 psychopharmacologic 61 Drug Metabolism 61 insulin sensitizing 61 Kahalalide F 61 Patients Receiving 61 Psychiatric Disorders 61 Inflammatory Arthritis 61 Efficacious 61 Hypercholesterolemia 61 Intravenous Immunoglobulin 61 Aptamer 61 Incretin 61 Pharmacokinetic 61 serotonin reuptake 61 Peginterferon Alfa 2a 61 Sustained Release 61 cytostatic 61 Hematopoietic Stem Cells 61 Long Term Efficacy 61 Lymphocyte 61 Mouse Model 61 ERK phosphorylation 61 Refractory Hodgkin Lymphoma 61 Sipuleucel T 61 rivastigmine Exelon 61 Smooth Muscle 61 idiopathic Parkinson disease 61 Physiologic 61 Septic Shock 61 Insulin Resistance 61 Replacement Therapy 61 Tumor Necrosis Factor 61 antithyroid 61 Helicobacter pylori eradication 61 agomelatine 61 N methyl 60 Lamotrigine 60 panobinostat 60 Anti angiogenic 60 Antiarrhythmic 60 Kidney Function 60 ON #.Na 60 Excretion 60 Novel Inhibitor 60 Pioglitazone 60 TNF Alpha 60 Receptor Signaling 60 Oral Fingolimod 60 KRN# 60 Secondary Hyperparathyroidism 60 Olanzapine 60 thyrotropin 60 immuno modulatory 60 GW# [003] 60 Anti Inflammatory 60 Pharmacokinetic Study 60 IFN β 60 Neurotoxicity 60 mediated inhibition 60 PPARgamma 60 Nucleoside 60 Immunologic 60 Hypertensive Patients 60 Polymorphism 60 Tesamorelin 60 Apoptotic 60 Diabetic Neuropathy 60 Placebo Controlled Study 60 Prophylactic Treatment 60 reuptake inhibitor 60 Etanercept 60 HDAC Inhibitor 60 Cognitive behavioral 60 Dendritic cell 60 receptor subtypes 60 Preclinical Models 60 Protein Kinase C 60 Squalamine 60 Phase 2b Study 60 Double Blind Placebo 60 direct thrombin inhibitors 60 adrenoceptor 60 Dasatinib 60 Bipolar Mania 60 immune modulating 60 Pemetrexed 60 Randomized Double blind 60 Signaling Pathway 60 mineralocorticoid 60 antifibrotic 60 Therapeutic Targets 60 Teriflunomide 60 prucalopride 60 Pathologic 60 Olmesartan 60 Showed Significant 60 desipramine 60 Chemokine Receptor 60 Mycophenolate Mofetil 60 alpha GAL 60 Molecular Basis 60 Antiviral Therapy 60 Lipid lowering 60 Schizophrenia Treatment 60 Pharmacokinetics PK 60 Myocardial Ischemia 60 neurotrophic 60 Renal Cell Carcinoma 60 Antiviral Activity 60 Hepatic Encephalopathy 60 #beta 60 histone deacetylase inhibitor 60 monoamine oxidase inhibitors 60 Imipramine 60 Antigen Specific 60 immune modulatory 60 Histone Deacetylase 60 Autoimmune Diseases 60 Meta Analysis 60 NQO1 60 inverse agonist 60 Clusterin 60 antidepressant efficacy 60 Cytokines 60 pan HDAC inhibitor 60 Androxal TM 60 receptor antagonism 60 antitumor 60 Oncolytic Reovirus 60 Macrophage 60 Meets Primary Endpoint 60 Osteoarthritis Patients 60 Venlafaxine 60 interleukin IL -# 60 Immunosuppressive 60 Methylprednisolone 60 Neuroprotective Effects 60 pharmacologic 60 glutamatergic 60 allopregnanolone 60 Dose Response 60 Mucosal 60 Neurol 60 Beta Amyloid 60 Hepatocellular Carcinoma 60 viral kinetics 60 icatibant 60 Gefitinib 60 Chronic Heart Failure 60 mGlu2 3 60 Inflammatory Bowel Diseases 60 mGluR2 NAM 60 Technosphere ® 60 Janus kinase 60 partial agonist 60 Preclinical Studies 60 Placebo Controlled Trial 60 systemic antifungal 60 Castration Resistant Prostate Cancer 60 Randomized Double Blind Placebo 60 mTOR signaling 60 Protease Inhibitors 60 Granulocyte Colony Stimulating Factor 60 interferon IFN 60 Chemoprevention 60 selective agonists 60 Intramuscular 60 Novel Antibiotic 60 Synthetic Peptide 60 2A receptor agonist 60 Cytotoxic T 60 Severe Asthma 60 Blinatumomab 60 Zoloft sertraline 60 neuroleptics 60 IFN beta 60 Bivalirudin 60 dasatinib Sprycel 60 Novel Small Molecule 60 inducible nitric oxide synthase 60 Treated Patients 59 Thymosin Beta 4 59 Patients Treated With 59 Atypical Antipsychotic 59 Polymorphisms 59 J Clin 59 psychostimulants 59 Plus Ribavirin 59 von Willebrand Factor 59 Vildagliptin 59 tumorigenicity 59 Late Breaker 59 oestrogenic 59 Myelodysplastic Syndromes 59 Immunological 59 Pooled Analysis 59 Hormone Replacement 59 Allosteric 59 bortezomib Velcade 59 Preclinical Study 59 Enlarged Prostate 59 Hormone Refractory Prostate Cancer 59 mecamylamine 59 Breast Cancer Metastasis 59 Mutagenesis 59 Microtubule 59 ACE Inhibitors 59 Liver Injury 59 antithrombotic 59 Neurogenesis 59 Anticoagulation 59 Gastrointestinal Disorders 59 Hyperlipidemia 59 Genetic Variation 59 Novel Therapeutic 59 5 HT2A 59 Drug Candidate 59 Traficet EN 59 Golimumab 59 alpha 2a 59 orally inhaled migraine 59 Danazol 59 Cytarabine 59 Acute Ischemic Stroke 59 pertussis toxin 59 pharmacotherapeutic 59 estrogen receptor beta 59 Cyclooxygenase 59 immunomodulatory effects 59 Solid Tumors 59 RNAi Therapeutic 59 Diabetic Patients 59 ERK signaling 59 aripiprazole Abilify 59 Triapine R 59 Somatostatin 59 thalidomide Thalomid 59 metastatic malignant 59 peroxisome proliferator activated 59 Ischemic 59 HepG2 cells 59 Nocturia 59 Cellular Immunotherapy 59 Kinoid 59 nonpharmacological 59 Potent Antiviral Activity 59 Demonstrates Potent 59 Menopausal Symptoms 59 colorectal liver metastases 59 nonsteroidal 59 Drug Interactions 59 Adrenal 59 dopamine D2 59 Romidepsin 59 Cancer Res 59 Neurochemistry 59 antiresorptive 59 Tigecycline 59 Metabolites 59 HPA axis 59 beta 1a 59 Desvenlafaxine Succinate 59 Lp PLA 2 59 Combination Treatment 59 Disease Modifying 59 Upregulation 59 prostaglandin synthesis 59 Hematologic 59 Rheumatoid Arthritis 59 Immune Responses 59 Abatacept 59 Bosentan 59 Renal Cell Cancer 59 Investigational Treatment 59 Pemphigus 59 Erectile Dysfunction Drug 59 Nonspecific 59 antiepileptics 59 Leukotriene 59 Fludarabine 59 PDE inhibitors 59 ERalpha 59 Intranasal 59 Anticonvulsants 59 nicotinic acetylcholine receptor 59 Cognitive Function 59 leukotriene receptor antagonist 59 Irritable Bowel 59 dose dependently 59 TLK# 59 Relapsing Remitting Multiple Sclerosis 59 novel peptide 59 apoptosis inducing 59 Clinical Evaluation 59 Preclinical Evaluation 59 Crit Rev 59 Antitumor activity 59 Anti TNF 59 Inactivation 59 ST Segment Elevation 59 Safinamide 59 Presents Preclinical Data 59 peptide CGRP 59 Demonstrates Positive 59 Gastric Cancer 59 PPAR agonist 59 Controlled Study 59 Anti Tumor Activity 59 Conjugated 59 MEVACOR 59 Beta Blocker 59 Aflibercept 59 Neurobiological 59 Adenoma Prevention 59 quetiapine Seroquel 59 Pathway Inhibitor 59 Galantamine 59 serotonin reuptake inhibitor 59 Renal Function 59 Neurogenic 59 Investigational Agent 59 mitochondrial toxicity 59 Paliperidone ER 59 Suicidality 59 Mutation Analysis 59 antisense inhibitor 59 Refractory Angina 59 Ziprasidone 59 Investigational Drug 59 subcutaneous immunoglobulin 59 Myeloid 59 Non Responders 59 Leukocyte 59 peripherally acting 59 Fingolimod 59 pharmacologic approaches 59 Monotherapy 59 Cyclin E 59 Hsp# Inhibitor 59 Hematological Cancers 59 Synthase 59 Antimalarial 59 Prognostic Factors 59 TNFα 59 Immune Mediated 59 receptor inhibitor 59 Ischaemic 59 developmental neurotoxicity 59 noradrenergic 59 small molecule tyrosine 59 Psychotropic 59 Sapacitabine 59 Insulin Sensitivity 59 5 HT1A 59 Cachexia 59 benzimidazole 59 Randomized Controlled Trials 59 CEACAM1 59 Osteoarthritis Pain 59 chemopreventive agent 59 Effective Treatments 59 Anti depressant 59 Topiramate 59 Immunogenicity 58 Chronic Pelvic Pain 58 Vidaza azacitidine 58 rufinamide 58 Deforolimus 58 Autoimmune Disease 58 abacavir Ziagen 58 Protease Inhibitor 58 coadministration 58 Rheumatoid Arthritis Patients 58 Pegylated Interferon 58 Glycosylation 58 Tumor Progression 58 analgesic effects 58 antiandrogens 58 Mitoxantrone 58 mGluR2 58 Partial Onset Seizures 58 Oncolytic 58 Receptor Agonist 58 cMET 58 Teriparatide 58 Lubiprostone 58 Hemodialysis Patients 58 Bisphosphonate 58 Capsules CII 58 HMG CoA reductase inhibitors 58 Atopic Dermatitis 58 p# inhibitor 58 cinacalcet 58 Anticancer Agent 58 Microalbuminuria 58 Disease Progression 58 miR #a [001] 58 gabapentin Neurontin 58 Localized Prostate Cancer 58 immunostimulatory effects 58 Endothelial Function 58 neuroinflammatory 58 Investigational Compound 58 Toxicol 58 Pgp 58 Lupus Nephritis 58 erlotinib Tarceva 58 Cognitive Impairment 58 Alkaline Phosphatase 58 Antiviral 58 Severe Sepsis 58 RNA Interference 58 humanized monoclonal 58 receptor agonists 58 paroxetine Paxil 58 Prophylactic 58 GHRH 58 mu opioid 58 cytoprotective 58 Acute Stroke 58 Progenitor Cells 58 Cloretazine R 58 Chronic Renal Failure 58 antiarrhythmic 58 Gout Drug 58 pulmonary hypertension PH 58 Chemotherapeutic Agents 58 NMDA antagonist 58 Erythropoietic 58 Tolerability 58 FKBP# 58 conventional DMARDs 58 Cognitive Dysfunction 58 Phase 2b Clinical Trial 58 NS5A 58 Malignancies 58 blood clot dissolving 58 Previously Treated 58 Angiotensin Converting Enzyme 58 HLA DR4 58 primidone 58 AT1R 58 β2 58 Eculizumab 58 Intravenous immunoglobulin 58 Interferon Alfa 58 VEGF receptor 58 Myelodysplastic Syndrome MDS 58 IND Application 58 opioid induced 58 Angiogenic 58 Pivotal Phase III 58 Polycythemia Vera 58 Clinical Relevance 58 Monoclonal Antibodies 58 ergot alkaloids 58 plasma lipid 58 NMDA receptor antagonists 58 Gleevec resistant 58 Fluconazole 58 Beneficial Effects 58 Phase Ib Clinical Trial 58 insulin sensitizers 58 HCV SPRINT 58 Renal Impairment 58 Randomised 58 Neuronal 58 Chronic Sinusitis 58 Radiofrequency Ablation RFA 58 Phase IIa Clinical Trial 58 Differential Diagnosis 58 Montelukast 58 Systemic Sclerosis 58 Hepatitis C Infection 58 antiangiogenesis 58 Omacetaxine 58 potent anticancer 58 propranolol Inderal 58 Fungal Infections 58 Mg Usa 58 Peripheral Arterial 58 Pathogenesis 58 Carfilzomib 58 immunomodulatory 58 trastuzumab Herceptin ® 58 Romiplostim 58 S#P# 58 endothelin receptor 58 cardiotoxic 58 Chronic Myeloid Leukemia 58 GABA receptor 58 adalimumab Humira 58 pharmacological approaches 58 Phase 2a Clinical Trial 58 Adiponectin 58 gamma secretase inhibitors 58 Chronic Lymphocytic Leukemia 58 clobazam 58 Metabolic Disease 58 serum cortisol 58 Vitro Activity 58 Degarelix 58 Polymerase Inhibitor 58 Pramlintide 58 Interferon Gamma 58 CEQ# 58 amisulpride 58 CRF antagonists 58 Methylphenidate 58 Inflammatory Pain 58 Hematopoietic 58 P2Y 58 Randomized Double Blind 58 tasimelteon 58 neuropeptide Y 58 MGd 58 Is Well Tolerated 58 oxcarbazepine 58 Protein Kinase 58 substrates inhibitors 58 diabetic gastroparesis 58 Prostacyclin 58 endothelial activation 58 antimuscarinic 58 Histopathological 58 MAPT 58 TRPV1 agonist 58 Th2 cytokines 58 Inflammatory Markers 58 nabilone 58 hepatotoxic 58 riociguat 58 Anti Infective 58 PDE4 58 costimulation 58 Prospective Multicenter 58 Successfully Completes Phase 58 anti leukemic 58 alpha 2A 58 Hyperphosphatemia 58 Aplidin R 58 ß blockers 58 neuroregenerative 58 lymphangiogenesis 58 secondary hyperparathyroidism 58 glatiramer acetate 58 Immunohistochemical 58 Iron Overload 58 Tumor Suppressor 58 hypothalamic pituitary adrenal axis 58 Placebo controlled 58 Dose Ranging Study 58 glucocorticoid 58 Prostaglandin 58 levocetirizine 58 PYY #-# 58 polyarticular 58 Well Tolerated 58 STRIDE PD 58 YONDELIS 58 Cognitive Deficits 58 Quantitation 58 lymphomas leukemias 58 EGFR HER2 58 Lipid Lowering 58 Tasimelteon 58 pregabalin Lyrica 58 paroxetine sertraline 58 Mutational 58 Present Preclinical Data 58 Therapeutic Efficacy 58 isoproterenol 58 Celecoxib 58 Dose Finding 58 multitargeted 58 Dual Opioid TM 58 Intravesical 58 depsipeptide 58 immunoregulatory 58 ritonavir boosted 58 immunostimulatory 58 Tumor Response 58 Inflammatory Diseases 58 SR# [004] 58 Menstrual Pain 58 Phosphatase 58 Urinary Incontinence 58 Mesenchymal Stem Cells 58 Systemic Delivery 58 Hedgehog Pathway Inhibitor 58 Beta Blockers 58 inotropes 58 FUS1 58 Cilostazol 58 Ropinirole 58 CYT# potent vascular disrupting 58 Levels Linked 58 Lymphoid 58 Predisposition 58 monoamine 58 Soft Tissue Sarcoma 58 antiandrogen 58 Tumor Growth 58 T1DM 58 Angiotensin 58 Chemotherapeutic 58 somatostatin 58 Potent Anti 58 Targeted Therapy 58 PI3K/mTOR 58 upregulates 58 Post Operative 58 R lenalidomide 58 Tumor Angiogenesis 58 Phospholipase A2 58 annexin 58 Anti Depressant 58 topically administered 58 Rheumatoid Arthritis RA 58 Multicenter Study 58 Int J 58 GLP 1R 57 Chronic Myelogenous Leukemia 57 Arch Neurol 57 J Consult Clin 57 Progressive Multifocal Leukoencephalopathy 57 Osteopontin 57 Conjugates 57 Cutaneous T 57 5 HT2A receptor 57 Antiepileptic Drug 57 agonists antagonists 57 Anticancer Activity 57 PPARγ 57 ARRY # 57 CYP#A# CYP#D# 57 Adefovir 57 Actinic Keratosis 57 Peginterferon 57 Chimeric 57 Predict Response 57 CB2 receptor 57 cetuximab Erbitux R 57 Cyclophosphamide 57 Adalimumab 57 antibiofilm 57 Transcranial Magnetic Stimulation TMS 57 ropinirole Requip 57 von Willebrand 57 enzyme inhibitors 57 potent antiproliferative 57 anti amnesic 57 Glypromate 57 Therapeutic Effects 57 HDACi 57 tryptase 57 Depressive Symptoms 57 CCR2 57 Cancer Vaccines 57 Bevacizumab 57 Novel Treatments 57 antihyperglycemic 57 Azacitidine 57 irreversible inhibitor 57 Adenoma 57 Postmenopausal Women 57 Antagonists 57 hydroxamic acid 57 EVIZON TM 57 Demonstrated Significant 57 alpha#beta# 57 nonpharmacologic 57 RhuDex 57 VMAT2 57 Subgroup Analysis 57 Controlled Release 57 Panic Disorder 57 Cardiac Stem Cell 57 mGluR5 antagonist 57 Fabry Disease 57 Sexual Dysfunction 57 Biological Effects 57 Endometrial 57 cAMP signaling 57 Cell Adhesion 57 Neurodegenerative Disease 57 Combination Therapy 57 renal fibrosis 57 receptor modulators 57 Selective serotonin reuptake inhibitors 57 Hepatitis C Virus 57 recurrent glioblastoma multiforme 57 M1 muscarinic 57 overactive bladder symptoms 57 Tipranavir 57 Bioequivalence 57 ara C 57 antiproliferative 57 atypical neuroleptics 57 Neurodegenerative 57 psychopharmacological 57 Ischemic Stroke 57 Ecallantide 57 NK1 57 beta blockers calcium 57 Extracellular Matrix 57 TNFa 57 potent inhibitors 57 receptor blocker 57 antiarrhythmic drug 57 adrenal suppression 57 mGluR5 inhibition 57 Cell Proliferation 57 receptor PPAR 57 Glimepiride 57 T2DM 57 targeted antifolate 57 protein kinase inhibitors 57 nucleoside analog 57 VAPRISOL 57 RNAi Therapeutics 57 Genetic Marker 57 Complicated Skin 57 Diastolic Heart Failure 57 Signaling Pathways 57 antiangiogenic agents 57 Nicotinamide 57 cyclin dependent kinase inhibitor 57 Renal Cancer 57 antioxidant supplementation 57 Anidulafungin 57 Acute Coronary Syndromes 57 gefitinib Iressa 57 Therapeutic Agents 57 Hyperkalemia 57 Tyrima 57 endothelin receptor antagonists 57 druggable target 57 Monoclonal Antibody 57 endogenous opioid 57 Phase 2b Trial 57 antitumor effect 57 anti CD3 antibody 57 thyroid hormone receptor 57 Tumor Microenvironment 57 Subcutaneous 57 Diabetic Foot Ulcer 57 pimozide 57 zonisamide SR 57 HIF PH inhibitors 57 imatinib resistance 57 Acute Coronary Syndrome 57 Paediatr 57 Tolvaptan 57 COX2 57 Therapeutic Antibody 57 histone deacetylases 57 Initiate Phase 57 hydroxocobalamin 57 Bipolar Depression 57 Sudhir Agrawal D.Phil 57 angiotensin receptor 57 Monoclonal 57 histone deacetylase 57 busulfan 57 Leukemias 57 anti secretory 57 radiolabeled 57 aminotransferase 57 Systematic Review 57 acting inhaled anticholinergic 57 acetylcholinesterase 57 Shows Statistically Significant 57 Drug Shows Promise 57 alpha blocker 57 nicotinic 57 IL# PE#QQR 57 plasma renin activity 57 Statistically Significant 57 beta arrestin 57 Elderly Patients 57 vasodilators 57 Prodrug 57 Single Dose 57 Randomized controlled 57 Vasopressin 57 CYP #D# 57 Neural Stem Cells 57 IFN α 57 Synta Announces 57 #:#-# [031] 57 CCX# B 57 Shows Promise Against 57 β blockers 57 Treat Parkinson Disease 57 Randomized Phase II 57 MET VEGFR2 57 hepatic insufficiency 57 CNS depressant 57 Fibroblast 57 Molecular Mechanism 57 Amino Acid